Profiling of Rigosertib Identifies Distinct Classes of Responders in Myelodysplastic Syndrome
Notable Labs has developed an automated, high-throughput, drug sensitivity testing platform based on multi-parameter flow cytometry to analyze peripheral blood and bone marrow samples from patients with hematologic malignancies. Primary samples undergo red blood cell lysis and are resuspended in media supplemented with various cytokines to support cells in culture for the duration of the assay. In addition to dysplastic cells and malignant blasts, normal immune cell components are retained in culture to preserve the tumor microenvironment. Cells are aliquoted into 384-well microtiter plates for drug screening. The automated system then dispenses nanoliter volues of investigational and FDA-approved compounds and combinations into each well, in replicates, and incubates for a specified period of time. Upon assay readout, the drugged aliquots are stained with a flow cytometry antibody panel to
quantify surface proteins to define specific immune cell populations. Drugged conditions are normalized to vehicle-only controls in an individual patient sample.
Learn how Notable’s Profiling of Rigosertib accelerated a company’s drug discovery program by enabling rapid identification of novel drug candidates for two targets.